| Company Name: | Vanda Pharmaceuticals Inc | | | Ticker Symbol: | VNDA | | CIK Number: | 0001347178 | | WWW Address: | http://www.vandapharma.com |
| CEO: | Dr. Mihael Hristos Polymeropoulos,M.D. | | No. of Employees: | 142 |
| Common Issue Type: | CS | | Business Description: | Vanda Pharmaceuticals Inc. is a biopharmaceutical Company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 21.11 |  0.0 | 20.58 | 20.8 | | 21.14 | 19.70 | 3571 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 1,107.2 | 52.4 | 0.00 | -0.35 | 0.00 | 0.0 | 0.0 | 33.44 - 13.88 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 21.11 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 1,107.2 | mil |
| Latest Shares Outstanding | 52.4 | mil |
| Earnings pS (EPS) | -0.35 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 604,700 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 50.9 | mil |
| Float as % of Shares Outstanding | 1.0 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.20 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | 0.0 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 0.0 | % |
| Current Ratio | | |
| Leverage Ratio (Assets/Equity) | | |
| Interest Cover | | |
| Total Debt/Equity (Gearing Ratio) | | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 1.90 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 4.98 | $ |
| Tangible Book-Value pS | 2.01 | $ |
| Cash Flow pS | 0.36 | $ |
| Free Cash Flow pS | -0.15 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.80 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | 52.6 | |
| Price/Free Cash Flow | | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 11.8 | | 1,932,686 | |
| 4 Weeks | 31.00 | 17.05 | 30.03 | -33.0 | | 1,305,891 | 24,811,943 |
| 13 Weeks | 33.44 | 17.05 | 23.60 | -14.7 | | 893,619 | 53,617,171 |
| 26 Weeks | 33.44 | 17.05 | 21.10 | -4.6 | | 915,009 | 113,461,192 |
| 52 Weeks | 33.44 | 13.88 | 17.30 | 16.3 | | 743,692 | 185,923,125 |
| YTD | 31.39 | 17.05 | - | -25.5 | | 1,013,958 | 32,446,687 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 19.21 | 20.44 | 25.97 | 23.07 | 21.69 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | | 0.0 | |
| Income | | 0.0 | |
| Dividend | | 0.0 | |
| Capital Spending | | NA | |
| R&D | 5.32 | NA | 50.96 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -0.9 | -0.9 | 4.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.13 | 0.13 | -0.63 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 48.43 |
| Current Ratio | 2.4 |
| Quick Ratio (Acid Test) | 2.3 |
| Liquidity Ratio (Cash) | 2.52 |
| Receivables Turnover | 8.7 |
| Average Collection Period | 41 |
| Working Capital/Equity | 75.7 |
| Working Capital pS | 2.19 |
| Cash-Flow pS | -0.04 |
| Free Cash-Flow pS | -0.08 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 9.06 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 0.0 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 2.8 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 4.84 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -64.01 |
| Enterprise Value (EV)/Free Cash Flow | -269.25 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 3.80 |
| Price/Cash Flow Ratio | 52.6 |
| Price/Free Cash Flow Ratio - LTM | |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 139.3 |
| 5-Y Low P/E Ratio | 28.8 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | -6 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.61 |
| Tangible Book Value pS - LTM | 2.01 |
| Book Value pS - LTM | 4.98 |
| Capital Invested pS | 2.51 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | 0.36 |
| Free Cash Flow pS - LTM | -0.15 |
| Earnings pS (EPS) | -0.35 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -2.21 |
| Free Cash Flow Margin 5YEAR AVG | -59.43 |
| Net Profit Margin | -0.1 |
| Net Profit Margin - 5YEAR AVRG. | |
| Equity Productivity | 1.26 |
| Return on Equity (ROE) | -0.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | |
| Capital Invested Productivity | 1.26 |
| Return on Capital Invested (ROCI) | -0.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | -0.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | -0.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 420,429 |
| Revenue per Employee | 604,700 |
| Net Income per Employee | |
| Average Collection Period | 420,429 |
| Receivables Turnover | 8.7 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 22.0 |
| Inventory/Sales | 0.5 |
| Accounts Payble/Sales | 0.00 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 1.66 |
| Fixed Assets Turnover | 4.64 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 4.91 |
| Revenue per $ Plant | 31.11 |
| Revenue per $ Common Equity | 1.26 |
| Revenue per $ Capital Invested | 1.26 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 75.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 23.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 23.4 |
|
|  
| | |  |  | | |
